Targeting LINC00284 using antisense oligonucleotides has been shown to suppress cell survival and tumor growth in triple-negative breast tumors (Vidovic et al., 2020), and to contribute to reduced angiogenesis in ovarian cancer (Ruan and Zhao, 2019). The gene discussed is NRAD1; the disease is neoplasm.